Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis

This network meta-analysis, which included 1689 patients from five randomized controlled trials and four other studies, compared the efficacy and safety of different JAK inhibitors in treating alopecia areata (AA). The results showed that oral baricitinib and ruxolitinib significantly improved patient response rates and had better safety profiles compared to placebo and conventional steroid treatments. Oral baricitinib, tofacitinib, and ruxolitinib also significantly improved complete response rates. Non-oral JAK inhibitors were less effective. The study concludes that oral baricitinib and ruxolitinib are excellent options for AA treatment, but further research is needed to determine the optimal dosing.